Drugs / HER-2 vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01376505 | Jun 2011 → Nov 2022 | breast cancer, gastrointestinal stromal tumor, malignant colon neoplasm, ovarian cancer | Robert Wesolowski | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HER-2 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01376505 ↗ |
| Modality | Vaccine | “HER2/neu peptide vaccine” NCT01376505 ↗ |
| Route | Intramuscular | “intramuscularly (IM)” NCT01376505 ↗ |